Trends in phase 1 oncology clinical trials across Australia; Analysis of ClinicalTrials.gov 2012-2022

被引:0
|
作者
Hitchen, Nadia [1 ]
Shahnam, Adel [1 ]
Manoharan, Sathya [1 ]
Topp, Monique [1 ]
Mileshkin, Linda [1 ,2 ]
Lim, Annette M. [1 ,2 ]
Whittle, James R. [1 ,2 ,3 ]
Luen, Stephen J. [1 ,2 ]
Solomon, Benjamin [1 ,2 ]
Lackovic, Kurt [4 ]
Desai, Jayesh [1 ,2 ,4 ]
Tran, Ben [1 ,2 ,3 ,4 ]
机构
[1] Peter MacCallum Canc Ctr, Med Oncol, Melbourne, Australia
[2] Univ Melbourne, Sir Peter MacCallum Dept Oncol, Melbourne, Australia
[3] Walter & Eliza Hall Inst Med Res, Personalised Oncol Div, Parkville, Australia
[4] Canc Trials Australia, Melbourne, Australia
关键词
Australia; cancer; early phase; oncology;
D O I
10.1111/ajco.14100
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BackgroundPhase 1 oncology trials provide access to new therapies and may improve cancer outcomes. Phase 1 trials conducted in the Asian-Pacific region are increasing at a faster rate than the global trend. This study aimed to describe the changing landscape of phase 1 oncology trials in Australia in the last decade.MethodsThis cross-sectional study reviewed phase 1 oncology trials registered on ClinicalTrials.gov conducted in Australia. Phase 1 trials were included for analysis if they enrolled adults with solid organ malignancies, used at least one systemic agent, and were first registered between January 1, 2012, and December 31, 2022. The number of trials, site locations, sponsor type, and drug class were analyzed using descriptive statistics.ResultsOver the 10-year period, ClinicalTrials.gov included 493 phase 1 clinical trials across 71 Australian sites. Most sites were in metropolitan locations; in Melbourne, trials were concentrated within selected sites, while in Sydney, trials were spread across a larger number of sites. The number of phase 1 trials per annum increased from 18 in 2012 to 75 in 2022. Since 2020, emerging biopharmaceutical companies have become the predominant sponsor type, a trend that is also seen globally. While most trial sponsors were North American (42%), there was increasing representation from Asian sponsors over the 10-year period (6% in 2012 to 39% in 2022). Immunomodulatory (45%) and targeted approaches (44%) accounted for most drug classes used alone or in combination.ConclusionsThere are an increasing number of phase 1 trials conducted within Australia. Sponsors of phase 1 trials are increasingly from Asian countries and are more likely to be emerging biopharmaceutical companies. Early drug development of novel cancer therapeutics in Australia is increasinf through phase 1 oncology trials Phase 1 trials across Australia have mostly utilised immunomodulatory and targeted approaches. image
引用
收藏
页数:7
相关论文
共 50 条
  • [1] TRENDS IN THE INCLUSION OF PATIENT REPORTED OUTCOMES IN ONCOLOGY CLINICAL TRIALS: ANALYSIS OF CLINICALTRIALS.GOV (2013-2022)
    Mordin, M.
    Castro, C.
    Gnanasakthy, A.
    [J]. VALUE IN HEALTH, 2023, 26 (06) : S325 - S325
  • [2] Characteristics of Phase IV Clinical Trials in Oncology: An Analysis Using the ClinicalTrials.gov Registry Data
    Henry, Brandon Michael
    Lippi, Giuseppe
    Nasser, Ameen
    Ostrowski, Patryk
    [J]. CURRENT ONCOLOGY, 2023, 30 (06) : 5932 - 5945
  • [3] Characteristics of Oncology Clinical Trials Insights From a Systematic Analysis of ClinicalTrials.gov
    Hirsch, Bradford R.
    Califf, Robert M.
    Cheng, Steven K.
    Tasneem, Asba
    Horton, John
    Chiswell, Karen
    Schulman, Kevin A.
    Dilts, David M.
    Abernethy, Amy P.
    [J]. JAMA INTERNAL MEDICINE, 2013, 173 (11) : 972 - 979
  • [4] Analysis of Clinical Trials in Radiation Oncology: A Systematic Characterization of the Clinicaltrials.gov Database
    Cihoric, N.
    Tsikkinis, A.
    Aebersold, D. M.
    Loessl, K.
    Zaugg, K.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 90 : S581 - S582
  • [5] Clinical Research in Surgical Oncology: An Analysis of ClinicalTrials.gov
    Menezes, A. S.
    Barnes, A.
    Scheer, A. S.
    Moloo, H.
    Boushey, R.
    Auer, R.
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2012, 19 : S138 - S138
  • [6] Clinical Research in Surgical Oncology: An Analysis of ClinicalTrials.gov
    Amber S. Menezes
    Alison Barnes
    Adena S. Scheer
    Guillaume Martel
    Husein Moloo
    Robin P. Boushey
    Elham Sabri
    Rebecca C. Auer
    [J]. Annals of Surgical Oncology, 2013, 20 : 3725 - 3731
  • [7] Clinical Research in Surgical Oncology: An Analysis of ClinicalTrials.gov
    Menezes, Amber S.
    Barnes, Alison
    Scheer, Adena S.
    Martel, Guillaume
    Moloo, Husein
    Boushey, Robin P.
    Sabri, Elham
    Auer, Rebecca C.
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2013, 20 (12) : 3725 - 3731
  • [8] Trends in the Location of Phase 3 Clinical Trials Between 2008 and 2012: A Retrospective Review Utilizing ClinicalTrials.gov
    Glass H.E.
    Glass L.M.
    Tran P.
    Jain A.
    [J]. Pharmaceutical Medicine, 2016, 30 (2) : 109 - 115
  • [9] Characterization of alopecia clinical trials: an analysis of trials registered on clinicaltrials.gov
    Konisky, Hailey
    Balazic, Eliza
    Kobets, Kseniya
    [J]. ARCHIVES OF DERMATOLOGICAL RESEARCH, 2024, 316 (04)
  • [10] Characterization of alopecia clinical trials: an analysis of trials registered on clinicaltrials.gov
    Hailey Konisky
    Eliza Balazic
    Kseniya Kobets
    [J]. Archives of Dermatological Research, 316